But, before the year comes to an end, I’m here to go over my 11 favorite moments from Marvel and DC’s movies and shows over ...

NEW YORK (AP) — “The Eras Tour was a lifetime within my life,” Taylor Swift told the room at a screening of the first two episodes of her new Disney+ docuseries, “The End of an Era.” “It feels insane.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, enhancing treatment strategies. Imetelstat (IME) has shown promising clinical ...

Luspatercept emerges as a preferred treatment for low-risk MDS, enhancing hemoglobin levels and quality of life, even in diverse patient subgroups. In managing patients with low-risk MDS and low ...

EL CENTRO, Calif. (KYMA) - For years, Shantal Montiel was the heartbeat of Kofa High School girls basketball. A four-year varsity starter, four-time MVP, and a four-year captain, Montiel didn't just ...

Taylor Swift is celebrating the end of an era with the people who made it all possible. On Tuesday in New York, the “Life of a Showgirl” songwriter held an intimate advance screening of the first two ...

Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis. The data presented at the American College of Rheumatology Convergence ...

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials. The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” ...

Disney has spent the past few years reshaping the MCU in ways that keep fans on their toes. The studio has introduced new characters, bid emotional farewells to longtime favorites, and replaced major ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability. The panel reviews why ...

Although great strides have been made in research for breast cancer vaccines, such a vaccine is likely years away from commercial availability, as an expert explained in an interview with CURE. As ...